ArticleRevista de neurologia2026
Evaluating the Value of Tissue-Based Assays in the Diagnosis of AE.
Article in Revista de neurologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundTissue-based assay (TBA) results can reveal the existence of antibodies other than known antibodies. Clinically, some patients with negative cell-based assay (CBA) but positive TBA have similar symptoms to autoimmune encephalitis (AE), indicating that positive TBA results still provide a certain reference for clinicians to make decisions. Through a retrospective study, the diagnostic rate of AE in our center and the auxiliary diagnostic value of TBA for AE were analyzed. The sensitivity and specificity of cerebrospinal fluid TBA in the diagnosis of AE were also evaluated.
methodsPatients who met the diagnostic criteria for confirmed and possible AE in our center were retrospectively selected. The positive and negative rates of TBA in patients diagnosed with AE were analyzed, as were the positive rate and subcellular localization of TBA in possible AE patients with a negative CBA.
resultsAmong the 61 cases of confirmed AE, 48 cases had positive TBA, resulting in a detection rate of 79%. There were 13 cases (21%) with false negatives. Among the 115 possible AE patients with negative autoantibodies, 97 cases (45.8%) had positive TBA. Based on the cellular morphology revealed by staining, these cases were categorized into neuronal cell staining (48 cases, including 8 cases with membrane staining, 19 cases with nuclear staining, and 21 cases with cytoplasmic antibody), glial cell staining (15 cases), and simultaneous staining of neuronal and glial cells (4 cases); The area under the curve of AE confirmed by TBA positivity diagnosis was 0.672, 95% CI 0.594-0.749,
conclusionsTBA serves as an effective complementary tool to CBA for AE diagnosis, with a sensitivity of 78.7% and specificity of 55.6%. Combining a positive TBA with an elevated cerebrospinal fluid (CSF) leukocyte count improved diagnostic specificity to 79.5%, suggesting that comprehensive evaluation integrating both assays can reduce missed diagnoses and optimize clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.